Patents Assigned to GrenPharma LLC
  • Publication number: 20100184724
    Abstract: The present invention generally relates to the treatment and/or prevention of Alzheimer's disease, other neurodegenerative diseases, and/or diseases characterized by the presence of certain metal ions, by using certain compositions including organosilicon compounds. A composition of the invention may be administered to a mammal, such as a human. In some cases, the composition may include a silanol, a silandiol, a silantriol, or a cyclic organosilane, and/or be able to form a silanol, a silandiol, or a silantriol upon exposure to physiological conditions such as are found in the blood, in the stomach and/or gastrointestinal tract, or in the brain or other organ. In certain cases, the organosilicon compound may be bound to a moiety able to be transported across the blood-brain barrier into the brain, for example, an amino acid, a peptide, a protein, a virus, etc. The organosilicon compound may also be labeled (e.g., fluorescently or radioactively) in certain instances.
    Type: Application
    Filed: September 25, 2009
    Publication date: July 22, 2010
    Applicant: GrenPharma LLC
    Inventors: Orrie Friedman, Ivan Correia, Toby J. Sommer, David Alan Kew
  • Patent number: 7595308
    Abstract: The present invention generally relates to the treatment and/or prevention of Alzheimer's disease, other neurodegenerative diseases, and/or diseases characterized by the presence of certain metal ions, by using certain compositions including organosilicon compounds. A composition of the invention may be administered to a mammal, such as a human. In some cases, the composition may include a silanol, a silandiol, a silantriol, or a cyclic organosilane, and/or be able to form a silanol, a silandiol, or a silantriol upon exposure to physiological conditions such as are found in the blood, in the stomach and/or gastrointestinal tract, or in the brain or other organ. In certain cases, the organosilicon compound may be bound to a moiety able to be transported across the blood-brain barrier into the brain, for example, an amino acid, a peptide, a protein, a virus, etc. The organosilicon compound may also be labeled (e.g., fluorescently or radioactively) in certain instances.
    Type: Grant
    Filed: May 17, 2005
    Date of Patent: September 29, 2009
    Assignee: GrenPharma LLC
    Inventors: Orrie Friedman, Ivan Correia, Toby Sommer, David Alan Kew
  • Publication number: 20090203644
    Abstract: The present invention generally relates to the treatment and/or prevention of Alzheimer's disease, other neurodegenerative diseases, and/or diseases characterized by the presence of certain metal ions, by using certain compositions including silicon-amino compounds. In some cases, a silicon-amino compound of the invention may be bidentate, tridentate, or otherwise polydentate, and in certain instances, the silicon-amino compound, or a portion thereof, may sequester aluminum or other ions, for example, by electrostatically binding the ions. Further aspects of the invention relate to methods of making and using such compositions of the invention, as well as articles and kits associated with the compositions.
    Type: Application
    Filed: October 24, 2005
    Publication date: August 13, 2009
    Applicant: GrenPharma LLC
    Inventors: Orrie Friedman, Thomas C. Pochapsky, Julie Yu Wei